Alamar Biosciences Inc.
ALMR | NASDAQ
$28.94
-$1.66 (-5.42%)
At close: Nov 2, 2026, 4:00 PM ET
$30.54
-$0.06 (-0.20%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q1 2025 Mar 31, 2025 |
|---|---|---|---|---|
Cash & Equivalents | 132.97M | 64.59M | 30M | 79.36M |
Short-Term Investments | 117.08M | n/a | n/a | n/a |
Long-Term Investments | 6.25M | 4.91M | n/a | n/a |
Other Long-Term Assets | 2.58M | 6.99M | 6.67M | n/a |
Receivables | 20.34M | 19.52M | 12.75M | n/a |
Inventory | 45.41M | 39.93M | 38.48M | n/a |
Other Current Assets | 15.58M | 12.53M | 13.47M | -79.36M |
Total Current Assets | 331.38M | 136.57M | 94.71M | n/a |
Property-Plant & Equipment | 49.16M | 36.14M | 36.63M | n/a |
Goodwill & Intangibles | 1.61M | 1.84M | 1.99M | n/a |
Total Long-Term Assets | 59.59M | 49.88M | 45.29M | n/a |
Total Assets | 390.98M | 186.45M | 139.99M | n/a |
Account Payables | 13.79M | 5.64M | 5.87M | n/a |
Deferred Revenue | 2.19M | 2.11M | 470K | n/a |
Short-Term Debt | 2.28M | 1.6M | 2.1M | n/a |
Other Current Liabilities | 4.55M | 11.61M | 7.59M | n/a |
Total Current Liabilities | 27.96M | 24.05M | 23.73M | n/a |
Long-Term Debt | 9.95M | 309.97M | 9.81M | n/a |
Other Long-Term Liabilities | 1.03M | 1.53M | 235.84M | -101.59M |
Total Long-Term Liabilities | 50.16M | 340.47M | 275.22M | -101.59M |
Total Liabilities | 78.12M | 364.52M | 298.95M | -101.59M |
Total Debt | 51.41M | 340.55M | 41.47M | n/a |
Book Value | 312.86M | -178.07M | n/a | n/a |
Book Value Per Share | 5.33 | -2.57 | n/a | n/a |
Common Stock | 7K | 1K | 1K | n/a |
Retained Earnings | -203.3M | -190.1M | -168.78M | n/a |
Comprehensive Income | -139K | -80K | -72K | -133.41M |
Shareholders Equity | 312.86M | -178.07M | -158.95M | 101.59M |
Total Investments | 123.34M | 4.91M | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove ALMR